260 related articles for article (PubMed ID: 26965290)
21. Outcomes of MDR/XDR-TB patients treated with linezolid: experience in Thailand.
Roongruangpitayakul C; Chuchottaworn C
J Med Assoc Thai; 2013 Oct; 96(10):1273-82. PubMed ID: 24350407
[TBL] [Abstract][Full Text] [Related]
22. Cigarette smoking and culture conversion in patients with susceptible and M/XDR-TB.
Reimann M; Schaub D; Kalsdorf B; Runge C; Carballo PS; Terhalle E; Salzer HJF; Lange C; Heyckendorf J
Int J Tuberc Lung Dis; 2019 Jan; 23(1):93-98. PubMed ID: 30674380
[TBL] [Abstract][Full Text] [Related]
23. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.
Muñoz-Torrico M; Caminero Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Ergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Rev Port Pneumol (2006); 2017; 23(1):27-30. PubMed ID: 28043788
[TBL] [Abstract][Full Text] [Related]
24. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.
Dauby N; Muylle I; Mouchet F; Sergysels R; Payen MC
Pediatr Infect Dis J; 2011 Sep; 30(9):812-3. PubMed ID: 21378593
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
26. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
27. Extensively drug-resistant tuberculosis in the United States, 1993-2007.
Shah NS; Pratt R; Armstrong L; Robison V; Castro KG; Cegielski JP
JAMA; 2008 Nov; 300(18):2153-60. PubMed ID: 19001626
[TBL] [Abstract][Full Text] [Related]
28. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
Gao M; Gao J; Xie L; Wu G; Chen W; Chen Y; Pei Y; Li G; Liu Y; Shu W; Fan L; Wu Q; Du J; Chen X; Tang P; Xiong Y; Li M; Cai Q; Jin L; Mei Z; Pang Y; Li L
Clin Microbiol Infect; 2021 Apr; 27(4):597-602. PubMed ID: 32553880
[TBL] [Abstract][Full Text] [Related]
29. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.
Vella V; Racalbuto V; Guerra R; Marra C; Moll A; Mhlanga Z; Maluleke M; Mhlope H; Margot B; Friedland G; Shah NS; Gandhi NR
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1170-5, i. PubMed ID: 21943840
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study.
Sharma SK; George N; Kadhiravan T; Saha PK; Mishra HK; Hanif M
Indian J Med Res; 2009 Oct; 130(4):392-5. PubMed ID: 19942741
[TBL] [Abstract][Full Text] [Related]
31. Treatment responses in multidrug-resistant tuberculosis in Germany.
Heyckendorf J; van Leth F; Avsar K; Glattki G; Günther G; Kalsdorf B; Müller M; Olaru ID; Rolling T; Salzer HJF; Schuhmann M; Terhalle E; Lange C
Int J Tuberc Lung Dis; 2018 Apr; 22(4):399-406. PubMed ID: 29562987
[TBL] [Abstract][Full Text] [Related]
32. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
33. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
34. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.
Migliori GB; Eker B; Richardson MD; Sotgiu G; Zellweger JP; Skrahina A; Ortmann J; Girardi E; Hoffmann H; Besozzi G; Bevilacqua N; Kirsten D; Centis R; Lange C;
Eur Respir J; 2009 Aug; 34(2):387-93. PubMed ID: 19282348
[TBL] [Abstract][Full Text] [Related]
35. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
37. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
Chang KC; Yew WW
Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
[TBL] [Abstract][Full Text] [Related]
38. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications.
Swaminathan A; du Cros P; Seddon JA; Quinnell S; Bobokhojaev OI; Dusmatova Z; Achar J
Int J Tuberc Lung Dis; 2016 Apr; 20(4):474-8. PubMed ID: 26970156
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study.
Russkikh A; Korotych O; Sereda Y; Samoilova A; Achar J; Yedilbayev A; Dara M; Vasilyeva I
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470087
[TBL] [Abstract][Full Text] [Related]
40. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
Yew WW
Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
